Previous 10 | Next 10 |
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023. The ...
Update includes supplemental information and provides additional time to complete regulatory review Biora anticipates remaining on track with its phase 1 clinical trial execution timeline SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), th...
Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Update to include supplemental information and allow additional time to complete regulatory review SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the...
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled ...
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust clinical device function data SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Biora Th...
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 Transaction results in a debt reduction of $50 million for the company On track to fi...
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023 ...
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device performance targets for the company’s BioJet™ platform for oral, systemic delivery of b...
NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJet™ systemic oral delivery platform device development achieved function targets while continuing to exceed...
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform f...
News, Short Squeeze, Breakout and More Instantly...
Progenity Inc. Company Name:
PROG Stock Symbol:
NASDAQ Market:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...